Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma
Conditions
Interventions
QVM149
Locations
25
Japan
Novartis Investigative Site
Koga, Fukuoka, Japan
Novartis Investigative Site
Yanagawa, Fukuoka, Japan
Novartis Investigative Site
Maebashi, Gunma, Japan
Novartis Investigative Site
Hiroshima, Hiroshima, Japan
Novartis Investigative Site
Sapporo, Hokkaido, Japan
Novartis Investigative Site
Tomakomai, Hokkaido, Japan
Start Date
April 28, 2017
Primary Completion Date
September 18, 2018
Completion Date
April 8, 2019
Last Updated
April 7, 2020
NCT07219173
NCT02327897
NCT07486401
NCT04706988
NCT04639791
NCT06471257
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions